Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move (CSE: $AGRA.C) (CSE: $DIXI_U.C) (CSE: $CURA.C) (TSXV: $RPP.V)
Delta, Kelowna, BC –May 30, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
AgraFlora Organics International Inc. (CSE: AGRA) (OTC: PUFXF), a growth oriented and diversified international cannabis company, announced that the Company has applied for licensing with Health Canada under the Industrial Hemp Regulations of the Cannabis Act.
The Company anticipates that license approval could be granted in the third quarter of 2019, which will subsequently equip AgraFlora with the ability to seed, cultivate and harvest industrial hemp at its flagship 2.2 million square foot Delta, BC facility.
Upon successful grant of an Industrial Hemp License, AgraFlora intends to aggressively pursue proprietary Cannabidiol ("CBD") cultivar development, as well as: Seedling development; Cultivar experimentation; and Specialized fibre production.
"We are thrilled to gain additional exposure to the burgeoning hemp and CBD marketplaces," said Brandon Boddy, Chairman and CEO of AgraFlora Organics International Ltd. "The cultivation of hemp is a natural accompaniment to our overall cannabis strategy, which will bring material synergies to our existing cultivation operations. By way of our existing cultivation infrastructure at the Delta Greenhouse Complex, we will continue to leverage the vast skillset of the Houwelings Group. Furthermore, AgraFlora's Industrial Hemp License will allow for ample access to low-cost, high-volume raw material for the extraction of CBD, which has been increasingly recognized for its therapeutic benefits across a wide range of medical indications and wellness applications."
Therabis LLC, a leading pet wellness company and a subsidiary of Dixie Brands Inc. (CSE: DIXI.U) (OTC: DXBRF), has announced that Vedco, Inc. will begin distributing its full-spectrum hemp-based, highly-palatable, soft-chew supplements to their network of distributors who are the leading suppliers to veterinary clinics across the USA.
Vedco is a logistics, sales and marketing provider of Animal Health products that is owned by many of the leading distributors in the US Animal Health Market and it creates a more efficient procurement infrastructure exclusively focused on servicing the veterinary channel. With a combined network of 98 distributor locations nationwide, Vedco is one of the country's largest veterinary suppliers with a client list that includes more than 30,000 clinics.
"We are pleased to have been selected by Vedco as the first full-spectrum soft chew hemp supplier that they are offering to their distribution network," said Bob Rubin, President of Therabis. "Many pet owners rely on their veterinarian to recommend a product that best addresses their pet's specific ailment. We expect that our participation in that channel will help strengthen our leadership position both among veterinary patients and retail consumers in general."
Therabis will introduce a series of new formulations of its products called "Therabis Veterinarian Formula," in recognition of the fact that pets requiring veterinary care are more likely to require stronger versions. These products will include higher concentrations of cannabinoids and other approved natural ingredients for more targeted therapeutic value in comparison to the formulations currently sold through retail and online channels. Therabis Veterinarian Formula versions will initially be available for the canine "Mobility" supplement, as well as both the canine and feline versions of the "Calming" stress relief products. Therabis will soon add other indication-specific veterinary formulas.
"We are very excited about a full-spectrum, plant-based nutraceutical derived from hemp in a soft chew dosage form that veterinary hospitals can offer to their clients for overall pet wellness," said Craig Campbell, General Manager of Vedco, Inc. "We have looked closely at Therabis products and we are pleased to showcase them to our full national distribution network."
Veterinarians are highly influential in recommending therapeutic products for pet owners. According to Packaged Facts, veterinarians are the most important source of pet care information for 70% of dog and cat owners, far surpassing any other source and more than doubling online research. The American Veterinary Medical Association recognizes nutraceutical therapy as important as part of their guidelines related to complimentary or alternative medicine. The nutraceutical market has been estimated by Grand View Research to exceed $2 billion in the U.S.
Continuing with Dixie Brands, who also issued a statement about the passage into law of Colorado bill HB19-1090, a bipartisan bill providing greater investment flexibility in marijuana businesses.
Dixie Brands supports the legislation and applauds the Colorado legislature and Governor Jared Polis for signing it into law. The Company also intends to explore opportunities to expand investment in Denver-based cannabis operations, once the law is fully in place.
"This is a defining moment for Colorado's cannabis industry and a tremendous boost to Colorado's economy," said Chuck Smith, CEO of Dixie Brands. "By permitting access to capital through private and public investments with appropriate guardrails, this bill ensures that Colorado businesses keep their headquarters in the state, remain competitive, invest in research and development and other innovation and continue to contribute significant tax dollars to the state."
Dixie and other publicly listed companies in Colorado have not been permitted to own cannabis production or manufacturing operations. Dixie owns the intellectual property and licensing rights associated with its portfolio of cannabis-infused products. The THC-infused products are manufactured and distributed in Colorado by a private state-licensed company controlled by an investor and Board Member of Dixie Brands. With the passage of HB19-1090, Dixie intends to explore a transaction to acquire and operate the licensed manufacturer. Any such transaction would be subject to successfully completing a state licensing application, as well as review by an independent committee of Dixie's Board.
In the event a transaction is completed, it would create expanded opportunities for Dixie to invest in its Colorado production operations as the Company continues to grow its business. Ownership of the manufacturing operation would result in increased revenue and gross margin for Dixie.
Chuck Smith is actively involved in the state's cannabis industry and has worked with other business leaders for the passage of HB19-1090. He currently sits as Board President of Colorado Leads, a pro-business alliance of more than 50 Colorado companies created to help educate the general public about the economic and community benefits of a safe, regulated medical and recreational cannabis industry.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), a leading vertically integrated cannabis operator in the United States, today announced that it completed the acquisition of the Emerald dispensary in Gilbert, Arizona, whose license is held by Absolute Healthcare, Inc., an Arizona non-profit corporation. The signing was announced earlier on May 21, 2019 and the transaction was closed on May 29, 2019. The dispensary is expected to be rebranded as Curaleaf over the next month.
Emerald is the only dispensary licensed to operate in the Town of Gilbert which is located in the Metro Phoenix area. It is one of Arizona's largest and longest standing medical cannabis retailers, serving over 44,000 unique patients since 2014.
Curaleaf has the largest footprint of single-branded retail stores in the U.S. and is executing on its strategy of building a national brand in highly populated states. Curaleaf will continue to explore opportunities to open additional locations throughout the state of Arizona in 2019.
Regent Pacific Group Limited (HK: 00575) (TSX-V: RPP), a specialist healthcare, wellness and life sciences investment group, has signed an indicative non-legally binding offer letter with Entertainment Direct Asia Ltd. to acquire Yooya for a potential consideration of US$15 million. If successful, the transaction would be effected through a share for share exchange.
Following the transaction, Yooya will expand its sector focus and become the first e-commerce marketing platform to focus on CBD infused products that are designed to awaken the body's natural healing system and promote better health and sleep; and products that safely eliminate the psychoactive THC from hemp.
Yooya is a content-driven e-commerce platform that is reshaping the way that brands connect with Chinese consumers. Total e-commerce revenue in China is forecast to top US$1.8 trillion by 2022. Yooya recognises that the way that Chinese consumers shop and the factors that influence purchase decisions have changed dramatically, with video content consumption being the single most popular activity on the internet in China. Japan, Asia's second largest e-commerce market in dollar terms, will see nearly 90 million e-commerce shoppers by 2021.
Yooya helps brands to reach the right audiences through its targeted video platform; and substantial network of content producers and e-commerce providers. John Possman and Richard Myers, existing directors of Yooya, have over fifty years of experience combined in media, technology, and consumer products in Greater China, Japan, and other markets in Asia.
Yooya is particularly focused on brands in the beauty and cosmetics, health and wellness, apparel, and related sectors. Recent research from Kantar shows that in 2018 annual online sale of cosmetics, skincare, and personal-care products in China grew by 46%, 40% and 37% respectively.
Jamie Gibson, Chief Executive Officer of Regent Pacific, said, "We see huge opportunity to use the Yooya team's extensive experience in digital marketing and partnerships with both influencers and e-commerce platforms to support the roll out of our CBD, organics and natural formulations business, which require more targeted engagement to reach the end-consumer."
The possible acquisition remains subject to a number of pre-conditions, including completion of due diligence, respective approvals of the Company's and Yooya's boards and formal acquisition documentation to be agreed between the Company and each of Yooya's shareholders.
To further support the expansion into new product lines, the Company has also signed subscription agreements with Jim Mellon, Jamie Gibson and an experienced group of strategic investors including principals of JJR Capital and Abony Enterprises in CBD, organics and natural formulations for a total amount of approximately US$17.5 million in convertible loan notes.
"The capital raised through this offering will help us drive our rapid expansion into the fast-growing CBD segment, which is estimated to be worth up to US$15 billion in China alone by 2024, added Jamie Gibson. "We envisage rolling out our CBD business in Asia with a line of exceptional consumer-focused products initially in the health and wellness area, including topicals and balms, and working with the world's largest CBD manufacturers to build out our CBD brands over time. The participants in this offering include strategic investors in the Company who have generated very successful investment returns in the CBD market and we are grateful for their confidence in the Company."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
